Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients.


METHODS
Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected.


RESULTS
Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence.


CONCLUSIONS
This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.
De Cremoux
Patricia
P
Département de Biologie des Tumeurs, Institut Curie, 26 rue d'Ulm, 75231 Paris Cedex, France. patricia.de-cremoux@curie.net
Grandin
Laure
L
Diéras
Véronique
V
Savignoni
Alexia
A
Degeorges
Armelle
A
Salmon
Rémy
R
Bollet
Marc A
MA
Reyal
Fabien
F
Sigal-Zafrani
Brigitte
B
Vincent-Salomon
Anne
A
Sastre-Garau
Xavier
X
Magdelénat
Henri
H
Mignot
Laurent
L
Fourquet
Alain
A
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D011379:Prognosis; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D017395:Plasminogen Activator Inhibitor 1; D014568:Urokinase-Type Plasminogen Activator